Shanghai INT Medical Instruments Co Ltd

Shanghai INT Medical Instruments Co Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.36, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.26, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess liquidity. The company's free cash flow of 222.28 million CNY supports its operational flexibility and capacity to fund growth initiatives. Profitability metrics show a return on equity (ROE) of 10.97% and a return on assets (ROA) of 6.99%, both of which are in line with industry norms for medical equipment and supplies firms. The company's operating margin, derived from an operating income of 271.45 million CNY on revenue of 1.07 billion CNY, reflects a healthy margin profile, though the exact cohort median is not provided. The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic breakdown provided in the available data. This lack of geographic diversification may expose the company to regional economic or regulatory risks, though the extent of such exposure is not quantified in the available data. Looking ahead, the company is projected to maintain a stable growth trajectory, with no specific numeric deltas provided for the current or next fiscal year. Historical revenue growth is not explicitly stated, but the company's operating cash flow of 348.11 million CNY and free cash flow of 222.28 million CNY suggest a strong cash-generating capability. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates a potential liquidity constraint, though the company's current ratio and free cash flow suggest it is not immediately at risk of insolvency. No dilution sources are identified in the available data, and the company's shares outstanding remain unchanged between basic and diluted shares. Recent events, including filings and transcripts, are not detailed in the available data, limiting the ability to assess the company's recent strategic or operational developments.